摘要
In the issue of March 25,2021 of the New England Journal of Medicine,Newsome et al.published the results of a phase II clinical trial of semaglutide,a glucagon-like peptide-1 receptor agonist(GLP-1RA),given once-daily,subcutaneously for 72 weeks for the treatment of non-alcoholic steatohepatitis(NASH)(1).The authors found that among 230 NASH patients with fibrosis stage of F2 or F3 the primary endpoint of the study(NASH resolution with no worsening of fibrosis)was achieved in 59%of patients with semaglutide at a dose of 0.4 mg compared to 17%in the placebo group(OR 6.87;95%CI:2.60-17.63;P<0.001).
基金
CL and ES participated in the NN9931-4296 trial,which was funded by Novo Nordisk.
